Michael Andreou | Value & Access Lead, Rare Diseases, Biogen
Biogen

Michael Andreou is a market access and pricing leader with over 25 years access and commercial strategy experience in pharma and biotech. He has broad therapeutic area experience, especially in rare diseases, and is leading Biogen ex-US access & pricing strategy and execution currently focusing on Friedreich's Ataxia & Skyclarys. Michael has an MBA (Oxford), a health economics masters (LSE) and a molecular biology masters (Berkeley).